申请人:Boehringer Mannheim GmbH
公开号:US04321194A1
公开(公告)日:1982-03-23
Aziridine-2-carboxylic acid derivatives of the formula ##STR1## wherein X is a carboxyl, nitrile, alkoxycarbonyl or carbamoyl group, and R and R.sup.1 are various organic radicals, or pharmacologically acceptable salts thereof, exhibit marked immunostimulant activity, especially in conjunction with added chemotherapeutic agents such as a penicillin, a cephalosporin, a nitrofuran or chloramphenicol. Those compounds are new where X is a cyano group or an alkoxycarbonyl radical and R.sub.1 is a hydrogen atom, but R' is not an unsubstituted alkyl radical or an alkyl radical substituted by hydroxyl, alkoxy, dialkylamino, phenyl, 4-chlorophenyl or 4-methoxyphenyl or a vinyl radical substituted by a phenyl or methyl radical, or a cycloalkyl radical, a phenyl a 4-chlorophenyl, a 4-methoxyphenyl, an s-triazinyl or a pyridinyl radical; or where X is a carbamoyl group and R.sub.1 is a hydrogen atom, R' is not an unsubstituted cyclohexyl, alkyl or benzyl radical; or where X is a cyano group or an alkoxycarbonyl radical and R.sub.1 is a phenyl radical, R' is not an isopropyl, cyclohexyl, phenyl, benzyl or p-chlorobenzyl radical; or where R.sub.1 is a methyl radical, R.sup.1 is not a benzyl, p-chloro- or p- methoxybenzyl radical.
Aziridine-2-羧酸衍生物的化学式为##STR1## 其中X为羧基、腈基、烷氧羰基或氨基甲酰基,R和R.sup.1为各种有机基,或其药理学上可接受的盐,表现出明显的免疫刺激活性,特别是与添加的化疗药物如青霉素、头孢菌素、硝基呋喃或氯霉素结合使用时。这些化合物是新的,其中X为氰基或烷氧羰基基团,R.sub.1为氢原子,但R'不是未取代的烷基基团或被羟基、烷氧基、二烷基氨基、苯基、4-氯苯基或4-甲氧基苯基取代的烷基基团,或被苯基或甲基基团取代的乙烯基基团,或被环烷基基团、苯基、4-氯苯基、4-甲氧基苯基、s-三嗪基或吡啶基团取代的乙烯基基团;或X为氨基甲酰基基团且R.sub.1为氢原子时,R'不是未取代的环己基、烷基或苄基基团;或X为氰基或烷氧羰基基团且R.sub.1为苯基时,R'不是异丙基、环己基、苯基、苄基或对氯苄基基团;或R.sub.1为甲基基团时,R.sup.1不是苄基、对氯苄基或对甲氧基苄基基团。